News and Resources
News and resources
Monique Barbut, Hassatou N’Sele and Ingrid van Wees to join IFFIm Board of Directors
New board members bring diverse backgrounds in global development and finance London, 1 July 2021 – IFFIm, the International Finance Facility for Immunisation, has appointed three new global development and finance executives to its Board of Directors. Monique Barbut, President of World Wildlife Fund (WWF) France, Hassatou Diop N’Sele, Trea...
Sweden makes historic US$ 287 million commitment to IFFIm
On 15 April, at the “One World Protected” event to launch a campaign to raise US $2 billion for the Gavi COVAX Advance Market Commitment, Per Olsson Fridh, Sweden’s Minister for International Development Cooperation announced his country’s US$ 258.1 million (SEK 2.25 billion) in long-term funding to IFFIm to support the purchase and distributi...
IFFIm helps COVAX bring fair, global access to COVID-19 vaccines
With vaccine bonds, donors and private investors are tackling the toughest global health crisis in a century. In the spring of 2020, as the novel coronavirus began to envelop the world, it was clear that a vaccine, available everywhere, would be essential to stem the pathogen’s spread.
The Lay of the land
The Lay of the Land: Q&A with IFFIm Board Chair Kenneth Lay Ken Lay was just 24 and not yet out of law school when he went to work at the SEC and started his career in finance. That job, and the mentors he met, set Ken on a career that brought him to the World Bank, where he earned a reputation as the architect of the modern bond market. As Ch...
Fatimatou Zahra Diop: trailblazer in finance and vaccine access
Against odds, Fatimatou Zahra Diop has seen opportunities for women rise in Senegal and beyond.
IFFIm Returns to Market with US$ 750 Million 5-year Oversubscribed Vaccine Bonds
IFFIm today priced US$ 750 million, 5-year fixed rate Vaccine Bonds that will provide Gavi, the Vaccine Alliance with immediately available funding to support routine immunisation in lower-income countries. The issuance, which is IFFIm’s second largest ever, will also accelerate the availability of critical funding for the Gavi COVAX Advance Market...
Italy reaffirms support of Gavi and CEPI with €5 million grant to IFFIm
Italy’s new grant will provide immediate funding for CEPI’s COVID-19 vaccine research and development programme.
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.